ArticleBMC nephrology2026
Longitudinal real-time PCR monitoring of CMV DNAemia and renal function in living-donor kidney transplant recipients with low immunological risk.
Article in BMC nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study evaluated the association between CMV DNAemia and renal function during the first 12 months after living-donor kidney transplantation in recipients with low immunological risk and explored differences in CMV DNAemia according to preemptive kidney transplantation status. MATERIALS AND
methodsA total of 112 living-donor kidney transplant recipients (mean age, 37.07 ± 14.41 years) were followed for 12 months. CMV DNAemia was monitored using quantitative real-time PCR targeting the UL55 (gB) gene. Longitudinal changes were analysed using Friedman and repeated-measures ANOVA, with the Mann -Whitney U test for between-group creatinine comparisons and the independent-samples t-test for GFR (p < 0.05).
resultsCMV DNAemia was detected in 25.9% of recipients. Among recipients with CMV DNAemia, serum creatinine differed significantly across the four time points (p = 0.004), whereas GFR showed no significant change over time (p = 0.278). At 6 months, serum creatinine was significantly higher in recipients with CMV DNAemia than in those with no DNAemia (1.38 (1.05-1.70) vs. 1.17 (0.93-1.40) mg/dL; p = 0.047), while the between-group difference in GFR did not reach statistical significance (p = 0.054). Recipients who underwent preemptive kidney transplantation had numerically lower CMV DNA levels at month 6 (491 vs. 1206 IU/mL) than those with a history of dialysis. Urine protein-to-creatinine ratio (UPCR) decreased significantly during follow-up (p < 0.001), while WBC (p = 0.004) and CRP (p = 0.014) changed significantly over time.
conclusionIn unadjusted analyses, recipients with CMV DNAemia had significantly higher serum creatinine levels at 6 months compared with those with no DNAemia, while the corresponding difference in GFR was not statistically significant. Differences according to preemptive kidney transplantation status were descriptive and should not be interpreted as evidence of a protective effect. Because of the observational design of the study, these findings should be interpreted with caution and confirmed in prospective studies.
Indexed as
Identifiers
42920107What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.